Eclosion Emerges to Fill A Swiss Start-Up Void
This article was originally published in Start Up
Despite being home to renowned research institutions and universities and mid- to large-size biopharma companies, Geneva, Switzerland, midway through the last decade, still lacked what it considered a vibrant life sciences start-up scene. A few years later and the Swiss region’s all-hands-on deck approach to building one has birthed a new hybrid model, the public/private endeavor Eclosion, which is one part early-stage incubator and another part venture fund.
You may also be interested in...
Red Script is a business accelerator whose purpose is to make early stage investments--either seed or Series A-- in companies developing riskier, but potentially transformative-types of science, such as regenerative medicine or neurostimulation.
Corporate incubators at Pfizer and Biogen--designed to provide a supply of strategically aligned biotech assets to the parent pipeline--remain unproven. But they're among a range of experiments aimed at helping seed discovery-stage ventures
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.